Sight Diagnostics

Sight Diagnostics, with a last investment of $71.00M in a Series D round on 05 August 2020, is a groundbreaking player in the healthcare industry. The company's flagship product, Sight OLO, has redefined diagnostic testing by delivering a Complete Blood Count in a matter of minutes. This morphological-based digital blood diagnostics technology is universal, accessible, and promises rapid and precise health insights. The proprietary AI algorithms analyze 1,000 detailed images with unparalleled precision, allowing for critical health information to be obtained from just two drops of blood. The company has already made great strides with its initial breakthrough in Malaria detection, and has been deployed across 24 countries, conducting close to a million tests and saving countless lives. With its headquarters in Israel and offices in London, New York, and Tel Aviv, Sight Diagnostics has attracted investments from notable firms including OurCrowd, New Alliance Capital, Go Capital, Koch Disruptive Ventures, Longliv Ventures, and Clal Biotechnology Industries. In an industry where time is critical, Sight Diagnostics is leading the way in revolutionizing healthcare with its innovative diagnostic solutions.